The PDUFA (Prescription Drug User Fee Act) date for delgocitinib has not yet been publicly announced. This date represents the target by which the U.S. Food and Drug Administration (FDA) is expected to make a decision on a new drug application.
What is Delgocitinib and What is it For?
Delgocitinib is an oral Janus kinase (JAK) inhibitor. It is being developed for the treatment of adults with atopic dermatitis [1]. The drug works by inhibiting JAKs, which play a role in the immune system and inflammation [2].
Who is Developing Delgocitinib?
The development of delgocitinib is being handled by Concert Pharmaceuticals, Inc. [1].
When Might a Decision be Made?
While a specific PDUFA date for delgocitinib has not been set, the FDA typically reviews new drug applications within a certain timeframe. Information regarding the filing and review status can often be found on the FDA's website or through company press releases.
What is the Status of Delgocitinib's Approval Process?
Concert Pharmaceuticals submitted a New Drug Application (NDA) to the FDA for delgocitinib for the treatment of adults with atopic dermatitis in January 2023 [1]. The FDA's acceptance of this NDA signifies the formal start of its review process.
What is the Significance of a PDUFA Date?
The PDUFA date is a critical milestone in the drug approval process. It sets an expected deadline for the FDA to either approve the drug, issue a Complete Response Letter (indicating the application is not ready for approval), or request additional information. This date provides clarity for developers, investors, and patients regarding the potential availability of a new treatment.
What are the Next Steps After a PDUFA Date?
If delgocitinib receives FDA approval, the next steps would involve the drug's launch and availability to patients. If the FDA issues a Complete Response Letter, Concert Pharmaceuticals would need to address the issues raised by the agency before potentially resubmitting the application.
Sources:
[1] https://www.concertpharma.com/news-events/press-releases/detail/135/concert-pharmaceuticals-announces-submission-of-new-drug
[2] https://www.drugpatentwatch.com/drug/delgocitinib